Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Indexed In
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Directory of Research Journal Indexing (DRJI)
- Hamdard University
Useful Links
Recommended Journals
Share This Page
Muntane Jordi
Department of Oncology Surgery
Seville Biomedical Research Institute
Spain
Biography
Dr.Muntané obtained his doctorate in physiology at the University of Barcelona (1992). He developed different research projects in the Karolinska Institute (Sweden) and INSERM U-128 (France) focused in the response of liver during acute and chronic inflammation (Muntane-Relat et al., 1995). Dr.Muntané moved to the “Reina Sofia” University Hospital (Córdoba, Spain) in 1995,where he studied the beneficial properties of nitric oxide-derived PGE administration during experimental liver injury (Muntané et al.2000; Siendones et al. 2004). The intracellular mechanisms of different antioxidants (α-tocopherol, N-acetylcysteine, Coenzyme Q) were also assessed in different experimental model of cytotoxicity in primary culture of human hepatocytes (González et al. 2007;González et al. 2011). Dr.Muntané joined the Biomedicine Institute of Seville (iBIS) (Seville, Spain) in 2011 where has developed different experimental strategies in liver cancer cells.
Research Interest
The multidisciplinary approaches of our research group allow us the identification of the role of p53 gene family members in different aspects related to tumor progression in patients with hepatocarcinoma and in different experimental models of hepatocarcinogenesis. We pay particular attention in the expression of cell death receptors and proliferation in liver cancer cells. Our main interest is to identify the molecular profile of patients with hepatocarcinoma which potentiates the antitumoral properties of actual antitumor strategies (sorafenib and everolimus).
Certificate
